NCT03386526View on ClinicalTrials.gov

APG-1387 in Patients With Advanced Solid Tumors or Hematologic Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

November 21, 2017

Primary Completion Date

October 31, 2022

Study Completion Date

November 30, 2022

Conditions
Advanced Solid Tumors or Hematologic Malignancies
Interventions
DRUG

APG-1387 for Injection

Multiple dose cohorts, 30 minute IV infusion, once weekly for 3 weeks of a 21-day cycle

Trial Locations (3)

48109

University of Michigan, Ann Arbor

49503

START Midwest, Grand Rapids

78229

The START Center for Cancer Care, San Antonio

Sponsors
All Listed Sponsors
lead

Ascentage Pharma Group Inc.

INDUSTRY